Search results for "Decapeptyl"

showing 2 items of 2 documents

Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endo…

2003

OBJECTIVE: The present study aims at demonstrating the equivalence of the 28-day and 3-month formulations of triptorelin SR (sustained release) in terms of percentage of patients achieving castration levels of estradiol (<==50 pg/mL) 84 days after treatment initiation. DESIGN: A phase II, prospective, randomized, multicenter, open study was conducted in two parallel groups of women with endometriosis. SETTING: Academic hospitals. PATIENT(S): Seventy-two women with endometriosis. were treated with a single intramuscular injection of 3-month triptorelin SR, and 74 patients were treated with one intramuscular injection of 28-day triptorelin SR every 28 days for 3 months. INTERVENTION(S): As pa…

Adultmedicine.medical_specialtyTime Factorsmedicine.drug_classChemistry PharmaceuticalPopulationEndometriosisUrologyEndometriosisInjections IntramuscularDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled triallawRecurrenceestrogenmedicineHumanseducationGynecologyeducation.field_of_studyTriptorelin PamoateEstradiolDecapeptylbusiness.industryendometriositriptorelinObstetrics and GynecologyMedical castrationLuteinizing Hormonemedicine.diseaseTriptorelinLuteolytic AgentsCastrationReproductive MedicinechemistryEstrogenPharmacodynamicsFemaleFollicle Stimulating HormoneIntramuscular injectionbusinessmedicine.drugFertility and sterility
researchProduct

Endocrine and Clinical Evaluation of 107 Patients With Advanced Prostatic Carcinoma Under Long-Term Pernasal Buserelin or Intramuscular Decapeptyl De…

1988

Three major assumptions emerged from these clinical and endocrine long-term studies. First, buserelin, given pernasally in the conventional doses, and Decapeptyl microcapsules administered intramuscularly in 5-week intervals are equally effective in terms of their long-term castration effect in previously untreated patients with prostatic carcinoma. However, Decapeptyl causes complete LH and subsequent testosterone down-regulation 1 week earlier than buserelin. Furthermore, this treatment is more convenient, and the compliance is better. Both LHRH analogues are equally well tolerated. Second, in groups of prostate cancer patients with far advanced disease treated with palliative intention, …

OncologyCancer Researchmedicine.medical_specialtybusiness.industryUrologymedicine.diseaseBuserelinchemistry.chemical_compoundProstate cancerCastrationOncologychemistryInternal medicineCarcinomaMedicineEndocrine systembusinessClinical evaluationDecapeptyl DepotTestosteronemedicine.drugAmerican Journal of Clinical Oncology
researchProduct